Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Nanosphere Receives FDA Clearance for C. difficile Test

Published: Wednesday, December 12, 2012
Last Updated: Wednesday, December 12, 2012
Bookmark and Share
Comprehensive sample-to-result test detects potentially deadly C. difficile and identifies 027 hypervirulent strain.

Nanosphere, Inc. announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance permitting marketing of its C.difficile test on the automated sample-to-result Verigene® System.

The C. difficile test expands Nanosphere’s infectious disease test capabilities.  C. difficile infection is a cause of diarrhea that can lead to colitis, other serious intestinal conditions and death.  In less than two hours, the C. difficile test detects the toxin A and B gene sequences of C. difficile and identifies the PCR ribotype 027 strain which is associated with increased severity of disease and used for infection control.  Early and accurate diagnosis of C. difficile infections is critical in both the proper treatment of infected patients and subsequent implementation of isolation and containment procedures to prevent further spread of the infection.

“The C. difficile test provides Nanosphere’s customers with a valuable tool to fight these deadly and costly infections,” said Bill Moffitt, Nanosphere’s Chief Executive Officer.  “With four new products cleared by the FDA in the last 12 months, we are pleased to lead the market in providing a comprehensive suite of tests that can improve patient outcomes and reduce healthcare spending” Moffitt stated.

The sample-to-result test automates the steps of bacterial DNA extraction, amplification, hybridization and target detection on the Verigene System.  The ease-of-use and rapid turnaround time of the test allow hospitals of any size to benefit from the speed and accuracy of automated molecular testing.

The C. difficile test complements Nanosphere’s broadening menu of infectious disease tests including:

•    Gram-Positive Blood Culture test (BC-GP) to detect bacteria, including antibiotic resistance markers, that may cause bloodstream infections (510(k) cleared; CE-Mark)
•    Respiratory Virus Plus test (RV+)  to detect multiple respiratory viruses which cause respiratory tract infections (510(k) cleared; CE-Mark)
•    Enteric Pathogens test (EP) to detect and multiple bacteria, viruses and toxin genes which cause gastrointestinal infections (In Clinical Trials )
•    Gram-Negative Blood Culture test (BC-GN) to detect bacteria, including antibiotic resistance markers, that may cause bloodstream infections (In Clinical Trials)

Nanosphere plans to commercialize the enteric pathogens and gram-negative tests in 2013 following receipt of the necessary regulatory approvals.

About C. difficile Infections

C. difficile strikes nearly 500,000 Americans annually and is linked in hospital records to more than 30,000 deaths per year in the United States.  The elderly, immunocompromised, and those recently treated with antibiotics have the greatest risk of acquiring C. difficile infections.  Around 75% of C. difficile infections are acquired in hospitals or nursing homes, with transmission to patients occurring via the hands of healthcare workers or contact with contaminated surfaces2.  Community-acquired cases of C. difficile, however, are on the rise.  The increase in severity of C. difficile infections over the past decade is likely linked to the emergence of the BI/NAP1/027 hypervirulent strain, with C. difficile related deaths increasing 400% over that timespan.  “Hospital billing data collected by the Federal Agency for Healthcare Research and Quality shows that more than 9% of C. diff-related hospitalizations end in death — nearly five times the rate for other hospital stays,” according to a recent USA TODAY investigation1.  Currently, the federal government does not have a system in place to track antibiotic use in healthcare facilities, and there is no Medicare and Medicaid penalty for facilities with high C. difficile rates.  A new C. difficile reporting rule is scheduled to be implemented in 2013 that will now include reporting in nursing homes and rehabilitation centers in addition to hospitals in attempts to combat C. difficile spread.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nanosphere Receives FDA Clearance for Respiratory Pathogens Test
Nanosphere, Inc. has announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Verigene® Respiratory Pathogens FlexNucleic Acid Test (RP Flex) on the automated sample-to-result Verigene System.
Wednesday, September 09, 2015
Nanosphere Receives FDA Authorization to Market its Gram-Positive Blood Culture Test
US FDA grants a de novo petition permitting marketing of Gram-Positive BC-GP on the automated Verigene® system.
Friday, June 29, 2012
Nanosphere Announces FDA Clearance of Second Molecular Diagnostics AssayHyper-coagulation Panel
The test is designed to detect disease-associated gene mutations that can contribute to blood coagulation disorders and difficulties metabolizing folate.
Wednesday, October 17, 2007
Nanosphere Awarded U.S. Patent for Biobarcode™ Protein Detection Technology
Biobarcode™ technology is designed for protein detection, for nucleic acid detection and genomics.
Friday, December 16, 2005
Nanosphere Names Dr. Peter G. Schultz to Board of Directors
Dr. Schultz's widely recognized scientific knowledge will enable him to provide strategic guidance to Nanosphere.
Thursday, September 29, 2005
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
Dementia Linked to Deficient DNA Repair
Mutant forms of breast cancer factor 1 (BRCA1) are associated with breast and ovarian cancers but according to new findings, in the brain the normal BRCA1 gene product may also be linked to Alzheimer’s disease.
Using Drug-Susceptible Parasites to Fight Drug Resistance
Researchers at the University of Georgia have developed a model for evaluating a potential new strategy in the fight against drug-resistant diseases.
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
New Discovery Sheds Light on Disease Risk
Gaps between genes interact to influence the risk of acquiring disease.
How Cells ‘Climb’ to Build Fruit Fly Tracheas
Mipp1 protein helps cells sprout “fingers” for gripping.
Research Finding Could Lead to Targeted Therapies for IBD
Findings published online in Cell Reports.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos